{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:11:46Z","timestamp":1787663506865,"version":"build-2736575974"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000265","name":"MRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK Department for International Development"},{"DOI":"10.13039\/501100000278","name":"DFID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MRC\/DFID"},{"name":"Career Development Fellowship"},{"name":"TMA"},{"name":"Career Development Fellowship"},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We examined virological outcomes, patterns of acquired HIV drug resistance (ADR), correlates of virological failure (VF) and acquired drug resistance among fisherfolk on first-line ART.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled 1169 adults on ART for a median duration of 6, 12, 24, 36 and \u226548\u2009months and used a pooled VL testing approach to identify VF (VL \u22651000\u2009copies\/mL). We performed genotyping among VF cases and determined correlates of VF and ADR by logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall virological suppression rate was 91.7% and ADR was detected in 71\/97 (73.2%) VF cases. The most prevalent mutations were M184V\/I (53.6%) for NRTIs and K103N (39.2%) for NNRTIs. Thymidine analogue mutations were detected in 21.6% of VF cases while PI mutations were absent. A zidovudine-based ART regimen, duration on ART (\u226524\u2009months) and secondary\/higher education level were significantly associated with VF. A nevirapine-based regimen [adjusted OR (aOR): 1.87; 95% CI: 0.03\u20130.54)] and VL \u226510000\u2009copies\/mL (aOR: 3.48; 95% CI: 1.37\u20138.85) were ADR correlates. The pooling strategies for VL testing with a negative predictive value (NPV) of \u226595.2% saved US $20320 (43.5%) in VL testing costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We observed high virological suppression rates among these highly mobile fisherfolk; however, there was widespread ADR among those with VF at the first VL testing prior to intensive adherence counselling. Timely treatment switching and adherence support is recommended for better treatment outcomes. Adoption of pooled VL testing could be cost effective, particularly in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkz261","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T15:12:44Z","timestamp":1559833964000},"page":"3021-3029","source":"Crossref","is-referenced-by-count":27,"title":["Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda"],"prefix":"10.1093","volume":"74","author":[{"given":"Jonah","family":"Omooja","sequence":"first","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"},{"name":"Department of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nannyonjo","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Sanyu","sequence":"additional","affiliation":[{"name":"Uganda Virus Research Institute, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella E","family":"Nabirye","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faridah","family":"Nassolo","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lunkuse","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kapaata","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farouk","family":"Segujja","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"},{"name":"Department of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Patrick","family":"Kateete","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda"},{"name":"Department of Immunology and Molecular Biology, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ssebaggala","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Bbosa","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Aling","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca N","family":"Nsubuga","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"},{"name":"Uganda Virus Research Institute, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9675-4234","authenticated-orcid":false,"given":"Deogratius","family":"Ssemwanga","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC)\/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda"},{"name":"Uganda Virus Research Institute, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,30]]},"reference":[{"key":"2019092005513480600_dkz261-B1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral society-USA panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"key":"2019092005513480600_dkz261-B2","year":"2018"},{"key":"2019092005513480600_dkz261-B3","year":"2014"},{"key":"2019092005513480600_dkz261-B4","year":"2016"},{"key":"2019092005513480600_dkz261-B5","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1097\/QAD.0b013e3283610ec7","article-title":"Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period","volume":"27","author":"Kyeyune","year":"2013","journal-title":"AIDS"},{"key":"2019092005513480600_dkz261-B6","first-page":"3","article-title":"Update on HIV-1 acquired and transmitted drug resistance in Africa","volume":"17","author":"Ssemwanga","year":"2015","journal-title":"AIDS Rev"},{"key":"2019092005513480600_dkz261-B7","year":"2017"},{"key":"2019092005513480600_dkz261-B8","doi-asserted-by":"crossref","first-page":"e0145536.","DOI":"10.1371\/journal.pone.0145536","article-title":"Virological response and antiretroviral drug resistance emerging during antiretroviral therapy at three treatment centers in Uganda","volume":"10","author":"Kaleebu","year":"2015","journal-title":"PLoS One"},{"key":"2019092005513480600_dkz261-B9","year":"2017"},{"key":"2019092005513480600_dkz261-B10","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/cid\/ciw128","article-title":"Emergence of acquired HIV-1 drug resistance almost stopped in Switzerland: a 15-year prospective cohort analysis","volume":"62","author":"Scherrer","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019092005513480600_dkz261-B11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1467-2679.2004.00153.x","article-title":"HIV and AIDS among fisherfolk: a threat to \u2018responsible fisheries\u2019?","volume":"5","author":"Allison","year":"2004","journal-title":"Fish Fisheries"},{"key":"2019092005513480600_dkz261-B12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/sti.2010.046805","article-title":"HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda","volume":"87","author":"Asiki","year":"2011","journal-title":"Sex Transm Infect"},{"key":"2019092005513480600_dkz261-B13","doi-asserted-by":"crossref","first-page":"e94932.","DOI":"10.1371\/journal.pone.0094932","article-title":"High incidence of HIV-1 infection in a general population of fishing communities around Lake Victoria, Uganda","volume":"9","author":"Kiwanuka","year":"2014","journal-title":"PLoS One"},{"key":"2019092005513480600_dkz261-B14","doi-asserted-by":"crossref","first-page":"1069.","DOI":"10.1186\/1471-2458-12-1069","article-title":"Alcohol consumption and risky sexual behaviour in the fishing communities: evidence from two fish landing sites on Lake Victoria in Uganda","volume":"12","author":"Tumwesigye","year":"2012","journal-title":"BMC Public Health"},{"key":"2019092005513480600_dkz261-B15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/09540120412331336698","article-title":"HIV\/AIDS in fishing communities: challenges to delivering antiretroviral therapy to vulnerable groups","volume":"17","author":"Seeley","year":"2005","journal-title":"AIDS Care"},{"key":"2019092005513480600_dkz261-B16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/cid\/ciq084","article-title":"Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting","volume":"52","author":"van Zyl","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019092005513480600_dkz261-B17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/QAI.0b013e3181ba37a7","article-title":"Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection","volume":"53","author":"May","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019092005513480600_dkz261-B18","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1097\/QAD.0b013e3283313ca9","article-title":"The use of pooled viral load testing to identify antiretroviral treatment failure","volume":"23","author":"Smith","year":"2009","journal-title":"AIDS"},{"key":"2019092005513480600_dkz261-B19","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/JCM.06689-11","article-title":"Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool","author":"Woods","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2019092005513480600_dkz261-B20","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2019092005513480600_dkz261-B21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1089\/aid.2015.0345","article-title":"Increased antiretroviral therapy use and virologic suppression in the Bronx in the context of multiple HIV prevention strategies","volume":"32","author":"Hanna","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019092005513480600_dkz261-B22","doi-asserted-by":"crossref","first-page":"e0127235.","DOI":"10.1371\/journal.pone.0127235","article-title":"Durable suppression of HIV-1 after virologic monitoring-based antiretroviral adherence counseling in Rakai, Uganda","volume":"10","author":"Billioux","year":"2015","journal-title":"PLoS One"},{"key":"2019092005513480600_dkz261-B23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12879-017-2428-3","article-title":"Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014\u2013July 2015","volume":"17","author":"Bulage","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2019092005513480600_dkz261-B24","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41598-018-37458-x","article-title":"Phylogeography of HIV-1 suggests that Ugandan fishing communities are a sink for, not a source of, virus from general populations","volume":"9","author":"Bbosa","year":"2019","journal-title":"Sci Rep"},{"key":"2019092005513480600_dkz261-B25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/QAI.0000000000000489","article-title":"Impact of age on retention in care and viral suppression","volume":"68","author":"Yehia","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019092005513480600_dkz261-B26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.qai.0000245886.51262.67","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine\/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes\u2014a 96-week analysis","volume":"43","author":"Pozniak","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019092005513480600_dkz261-B27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1874613601812010038","article-title":"Treatment outcome and adverse events of tenofovir disoproxil fumarate based regimens as compared to zidovudine based regimens among people living with HIV\/AIDS: a systematic review and meta-analysis of observational studies","volume":"12","author":"Kefale","year":"2018","journal-title":"Open AIDS J"},{"key":"2019092005513480600_dkz261-B28","doi-asserted-by":"crossref","first-page":"e68995.","DOI":"10.1371\/journal.pone.0068995","article-title":"Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis","volume":"8","author":"Pillay","year":"2013","journal-title":"PLoS One"},{"key":"2019092005513480600_dkz261-B29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","article-title":"HIV-1 drug resistance and resistance testing","volume":"46","author":"Clutter","year":"2016","journal-title":"Infect Genet Evol"},{"key":"2019092005513480600_dkz261-B30","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"Gregson","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2019092005513480600_dkz261-B31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2017.03.024","article-title":"Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration","volume":"18","author":"Rhee","year":"2017","journal-title":"EBioMedicine"},{"key":"2019092005513480600_dkz261-B32","doi-asserted-by":"crossref","first-page":"9.","DOI":"10.1186\/1742-6405-11-9","article-title":"HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study","volume":"11","author":"Hassan","year":"2014","journal-title":"AIDS Res Ther"},{"key":"2019092005513480600_dkz261-B33","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/cid\/ciu590","article-title":"Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-analysis","volume":"59","author":"Liu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019092005513480600_dkz261-B34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1473-3099(09)70328-7","article-title":"Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review","volume":"10","author":"Barth","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2019092005513480600_dkz261-B35","doi-asserted-by":"crossref","first-page":"e110749.","DOI":"10.1371\/journal.pone.0110749","article-title":"Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients","volume":"9","author":"Hofstra","year":"2014","journal-title":"PLoS One"},{"key":"2019092005513480600_dkz261-B36","first-page":"132","article-title":"2017 update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing","year":"2016","journal-title":"Top Antivir Med"},{"key":"2019092005513480600_dkz261-B37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hiv.12236","article-title":"Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial","volume":"16","author":"Baxter","year":"2015","journal-title":"HIV Med"},{"key":"2019092005513480600_dkz261-B38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N Engl J Med"},{"key":"2019092005513480600_dkz261-B39","year":"2018"},{"key":"2019092005513480600_dkz261-B40","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/jac\/dkr171","article-title":"Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study","volume":"66","author":"Prosperi","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2019092005513480600_dkz261-B41","first-page":"1749","article-title":"Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa","volume":"61","author":"Boender","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019092005513480600_dkz261-B42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/COH.0b013e32835b7f94","article-title":"Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa","volume":"8","author":"Hamers","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"2019092005513480600_dkz261-B43","doi-asserted-by":"crossref","first-page":"e109148","DOI":"10.1371\/journal.pone.0109148","article-title":"Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings","volume":"9","author":"Phillips","year":"2014","journal-title":"PLoS One"},{"key":"2019092005513480600_dkz261-B44","doi-asserted-by":"crossref","first-page":"440","DOI":"10.7326\/0003-4819-134-6-200103200-00008","article-title":"Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness","volume":"134","author":"Weinstein","year":"2001","journal-title":"Ann Intern Med"},{"key":"2019092005513480600_dkz261-B45","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1097\/QAD.0000000000001964","article-title":"HIV second-line failure and drug resistance at high- and low-level viremia in Western Kenya","volume":"32","author":"Kantor","year":"2018","journal-title":"AIDS"},{"key":"2019092005513480600_dkz261-B46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","article-title":"Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study","volume":"12","author":"Hamers","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2019092005513480600_dkz261-B47","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1089\/aid.2012.0123","article-title":"Short communication: HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral-naive individuals from Ugandan fishing communities of Lake Victoria","volume":"29","author":"Nazziwa","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019092005513480600_dkz261-B48","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jac\/dku426","article-title":"Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case\u2013control study using centralized ultrasensitive 454 pyrosequencing","volume":"70","author":"Cozzi-Lepri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2019092005513480600_dkz261-B49","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jcv.2014.05.011","article-title":"A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy","volume":"60","author":"Newman","year":"2014","journal-title":"J Clin Virol"},{"key":"2019092005513480600_dkz261-B50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/QAI.0b013e3182a61e63","article-title":"Pooled HIV-1 viral load testing using dried blood spots to reduce the cost of monitoring antiretroviral treatment in a resource-limited setting","volume":"64","author":"Pannus","year":"2013","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz261\/28885472\/dkz261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/10\/3021\/30039477\/dkz261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T14:57:40Z","timestamp":1663599460000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/10\/3021\/5525340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,30]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,6,30]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz261","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,6,30]]}}}